Payment overview · 2025
General Payments
$6,220.56
56 reported records · 11 companies
Healthcare provider profile · identity verified
Chun-Kit Chan, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · NEW YORK, NY · NPI 1730284308
Verified facts
What the public records show
CMS Open Payments records show Chun-Kit Chan, D.O. received $6,220.56 in general payments during 2025 across 56 reported records.
Gilead Sciences, Inc. accounted for 86.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Prolia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 226 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Shingrix by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $5,388.27 | 86.6% | 21 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $264.89 | 4.3% | 10 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $141.03 | 2.3% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $109.01 | 1.8% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $107.39 | 1.7% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $50.89 | 0.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $41.24 | 0.7% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $34.16 | 0.6% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $34.02 | 0.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26.65 | 0.4% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $23.01 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,860.00 | 3 |
| Food and Beverage | $1,360.56 | 53 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $235.62 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $235.62 | 9 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $109.01 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $107.39 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $77.20 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $50.89 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $41.24 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $34.02 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $26.65 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $23.01 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $16.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 88 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 53 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
38 | 22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
88 | 21 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
226 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
58 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1004 | 286 |
| Amlodipine Besylate | Amlodipine Besylate | 714 | 195 |
| Losartan Potassium | Losartan Potassium | 541 | 153 |
| Metformin Hcl | Metformin Hcl | 412 | 116 |
| Tamsulosin Hcl | Tamsulosin Hcl | 233 | 67 |
| Vemlidy | Tenofovir Alafenamide | 226 | 28 |
| Simvastatin | Simvastatin | 222 | 58 |
| Sertraline Hcl | Sertraline Hcl | 191 | 39 |
| Raloxifene Hcl | Raloxifene Hcl | 185 | 41 |
| Donepezil Hcl | Donepezil Hcl | 158 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 155 | 44 |
| Omeprazole | Omeprazole | 154 | 78 |
| Metoprolol Tartrate | Metoprolol Tartrate | 135 | 39 |
| Januvia | Sitagliptin Phosphate | 130 | 28 |
| Ammonium Lactate | Ammonium Lactate | 119 | 61 |
| Mometasone Furoate | Mometasone Furoate | 115 | 74 |
| Allopurinol | Allopurinol | 89 | 22 |
| Lisinopril | Lisinopril | 89 | 22 |
| Jardiance | Empagliflozin | 88 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 54 |
| Memantine Hcl | Memantine Hcl | 86 | 12 |
| Alendronate Sodium | Alendronate Sodium | 77 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 75 | 23 |
| Gabapentin | Gabapentin | 73 | 18 |
| Farxiga | Dapagliflozin Propanediol | 72 | 15 |
| Glipizide Er | Glipizide | 72 | 21 |
| Vascepa | Icosapent Ethyl | 69 | 15 |
| Ibuprofen | Ibuprofen | 67 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 65 | 15 |
| Finasteride | Finasteride | 63 | 18 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 58 | 24 |
| Xarelto | Rivaroxaban | 58 | 14 |
| Rybelsus | Semaglutide | 53 | 13 |
| Atenolol | Atenolol | 51 | 14 |
| Celecoxib | Celecoxib | 51 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 48 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 48 | 14 |
| Meclizine Hcl | Meclizine Hcl | 47 | 38 |
| Tradjenta | Linagliptin | 46 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 45 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 41 | 24 |
| Procto-Med Hc | Hydrocortisone | 41 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | 11 |
| Prolia | Denosumab | 38 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 20 |
| Azithromycin | Azithromycin | 37 | 34 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | 13 |
| Divalproex Sodium | Divalproex Sodium | 35 | suppressed |
| Glimepiride | Glimepiride | 35 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 35 | 16 |
| Ursodiol | Ursodiol | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Lidocaine | Lidocaine | 32 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | 11 |
| Fenofibrate | Fenofibrate,micronized | 31 | suppressed |
| Ranolazine Er | Ranolazine | 31 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 29 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Nitroglycerin | Nitroglycerin | 29 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 29 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | 16 |
| Montelukast Sodium | Montelukast Sodium | 27 | suppressed |
| Carvedilol | Carvedilol | 26 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 25 | suppressed |
| Entecavir | Entecavir | 25 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | 14 |
| Acarbose | Acarbose | 24 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Famotidine | Famotidine | 24 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 17 |
| Clonazepam | Clonazepam | 19 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Eliquis | Apixaban | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | 11 |
| Trazodone Hcl | Trazodone Hcl | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 14 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Livalo | Pitavastatin Calcium | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $6,220.56 · 56 records | Gilead Sciences, Inc. | Arikayce, Cologuard Collection Kit, EVENITY, Fluad, Flucelvax, GEMTESA, JARDIANCE, Ozempic, Rybelsus, SYNTHROID, TRELEGY ELLIPTA, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error